» Articles » PMID: 12499276

Expression of CXC Chemokine Receptor-4 Enhances the Pulmonary Metastatic Potential of Murine B16 Melanoma Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2002 Dec 25
PMID 12499276
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

The chemokine receptors CC chemokine receptor (CCR) 7 and CXC chemokine receptor (CXCR) 4 have been implicated in cancer metastasis. To evaluate whether CXCR4 is sufficient to increase tumor metastasis in an organ-specific manner, we transduced murine B16 melanoma cells with CXCR4 (CXCR4-B16) and followed the metastatic fate of the transduced cells in both i.v. and s.c. inoculation models of metastasis. CXCR4-B16 cells demonstrated marked increases (>10-fold) in pulmonary metastasis compared with vector (pLNCX2)-B16 after i.v. and s.c. inoculation of tumor cells. The increase in metastasis could be completely inhibited by T22, a small peptide antagonist of CXCR4. As early as 24 and 48 h after i.v. injection, CXCR4-B16 cells were significantly increased in the lung compared with control B16 cells by 5- and 10-fold (P < 0.05), respectively. CXCR4-B16 cells adhered better to both dermal and pulmonary microvascular endothelial cells relative to control B16 cells. Moreover, CXCL12 promoted the growth of CXCR4-B16 cells in vitro. Whereas expression of CXCR4 in B16 cells dramatically enhanced pulmonary metastasis, metastasis to the lymph nodes, liver, and kidney was rare. Immunohistochemical staining of both primary human cutaneous melanoma and pulmonary metastases revealed CXCR4 expression. Thus, CXCR4 plays a potentially important role in promoting organ-selective metastasis, possibly by stimulating tumor adhesion to microvascular endothelial cells and by enhancing the growth of tumor cells under stress.

Citing Articles

The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy.

Inverso D, Tacconi C, Ranucci S, De Giovanni M Eur J Immunol. 2024; 54(12):e2350870.

PMID: 39263783 PMC: 11628915. DOI: 10.1002/eji.202350870.


How chemokines organize the tumour microenvironment.

Mempel T, Lill J, Altenburger L Nat Rev Cancer. 2023; 24(1):28-50.

PMID: 38066335 PMC: 11480775. DOI: 10.1038/s41568-023-00635-w.


Sex-Based Disparities in Leukocyte Migration and Activation in Response to Inhalation Lung Injury: Role of SDF-1/CXCR4 Signaling.

Chatterjee T, Lewis T, Arora I, E Gryshyna A, Underwood L, Masjoan Juncos J Cells. 2023; 12(13).

PMID: 37443753 PMC: 10340292. DOI: 10.3390/cells12131719.


CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.

Bao S, Darvishi M, Amin A, Al-Haideri M, Patra I, Kashikova K J Cancer Res Clin Oncol. 2023; 149(10):7945-7968.

PMID: 36905421 DOI: 10.1007/s00432-022-04444-w.


Cancer metastasis chemoprevention prevents circulating tumour cells from germination.

Xie X, Li Y, Lian S, Lu Y, Jia L Signal Transduct Target Ther. 2022; 7(1):341.

PMID: 36184654 PMC: 9526788. DOI: 10.1038/s41392-022-01174-w.